More than 8,700 patients are now enrolled in over 450 active clinical trials at a major Gulf South health system, marking a significant expansion of access to experimental therapies in a region often underserved by cutting-edge research. The milestone was announced during the institution’s 23rd Annual Research Week, a five day event that showcased breakthroughs in oncology, precision medicine, and tobacco related disease research.
Of the total active trials, 181 focus specifically on oncology, reflecting a concentrated effort to develop new treatments for cancer. A key driver of this work is a strategic clinical integration with UT MD Anderson Cancer Center, which gives patients across eight cancer centers in South Louisiana access to early phase trials and state of the art therapies. Researchers highlighted how next generation sequencing and genomic profiling are now being used to identify actionable mutations, allowing clinicians to match patients with targeted therapies that maximize efficacy while reducing side effects.
Among the most promising approaches discussed was the use of antibody drug conjugates (ADCs) for gynecologic cancers. These therapies combine the targeting ability of monoclonal antibodies with potent cytotoxic agents, delivering a dual mechanism that selectively destroys malignant cells while sparing healthy tissue. Another featured presentation examined colorectal cancer evolution, using serial biopsies and circulating tumor DNA analysis to understand how tumors change over time and develop treatment resistance. The goal is to refine adaptive treatment strategies that respond to the molecular complexity of each patient’s cancer.
Award Honors Tobacco Research With Public Health Impact
The annual Alton Ochsner Award Relating Smoking and Disease was presented to Dr. Robin Mermelstein and Dr. Li-Shiun Chin for their work on nicotine dependence and cessation. Their research bridges behavioral science and molecular medicine, offering insights that directly inform public health policies and smoking prevention strategies. The award lectures are a longstanding tradition of Research Week, underscoring the institution’s commitment to translational research that moves from the lab to real world patient outcomes.
Looking ahead, the health system plans to continue expanding its research portfolio across oncology, precision medicine, pharmacy, and population health. With more than 150 abstracts submitted for the event and a strong mentorship program for early career investigators, leaders say the pipeline of new science remains robust. The goal is to ensure that patients across the Gulf South have access to novel therapies that are often unavailable elsewhere in the region, turning scientific discovery into tangible improvements in community health.